Research | Open | Published:
Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor
Molecular Cancervolume 10, Article number: 130 (2011)
uPA/uPAR is a multifunctional system that is over expressed in many cancers and plays a critical role in glioblastoma (GBM) invasion. Previous studies from our lab have also shown that uPA/uPAR down regulation inhibits cancer cell invasion in SNB 19 GBM cells.
As Notch 1 is known to be over expressed and promotes invasion in glioblastoma, we therefore tested our hypothesis of whether down regulation of uPA/uPAR, singly or in tandem, attenuates GBM invasion via Notch 1 receptor. Targeted down regulation of uPA/uPAR, either singly or simultaneously, inhibited the anchorage independent growth of U251MG and GBM xenograft cell lines 4910 and 5310 as assessed by soft agar colony formation assay. Expression of all four Notch receptors was confirmed in GBM tissue array analysis by immunohistochemistry.
Down regulation of uPA/uPAR, either singly or simultaneously, in U251 MG and tumor xenografts inhibited the cleavage of the Notch receptor between the Gly 1743 and Val 1744 positions, thereby suggesting inhibition of activated cytosolic fragment-related Notch gene transcription. Morphological analysis confirmed inhibition of NICD when U251 MG cells were treated with puPA, puPAR or pU2. uPA/uPAR down regulation inhibited Notch 1 mRNA in all three examined cell lines. uPA/uPAR shRNA down regulated nuclear activation of NF-κB subunits and phosphorylation of AKT/mTOR pathway in U251 MG and GBM xenografts. puPA down regulated NICD and HES induced phosphorylation of AKT/ERK and NF-κB. Down regulation of Notch 1 using siRNA inhibited uPA activity as shown by fibrinogen zymography. It also decreased uPA expression levels as shown by western blotting. Exogenous addition of uPA activated Notch 1 in uPAR antisense U251 MG cells and also in uPAR antisense cells transfected with siRNA against Delta and Jagged. The Notch 1 receptor co-localized with LAMP-1, a marker for lysosomes in uPA, uPAR and U2, down regulated U251 MG cells which probably indicates inhibition of Notch 1 receptor trafficking in GBM cells. Notch 1 expression was significantly inhibited in puPA- and pU2-treated pre-established intracranial tumors in mice.
Overall our results show that down regulation of uPA/uPAR, either singly or simultaneously, could be an effective approach to attenuate Notch 1 receptor cleavage, signaling and endosomal trafficking in U251MG cells and xenografts, and ultimately inhibiting GBM invasion.
In spite of the recent development of targeted therapies (e.g., Temozolomide and avastin), glioblastoma (GBM) still continues to be a medical challenge. Identification of novel targets such as uPA and uPAR that are over expressed in glioblastoma and understanding the different signaling pathways they regulate will greatly enhance the clinical treatment and outcome for patients affected with glioblastoma.
The uPA/uPAR system is a multifunctional system which is involved in several cellular processes like migration, angiogenesis and invasion. Studies by others and us have conclusively shown that the uPA/uPAR system significantly correlates to tumor aggressiveness and poor outcome. Our studies have also shown that shRNA constructs directed against uPA/uPAR, either singly or in combination, have a significant inhibitory effect on the migration, invasion and angiogenesis of GBM cells and xenografts.
Notch signaling is a highly conserved pathway playing an important role during embryo development and adulthood. In mammals, it consists of four receptors, namely Notch 1, Notch 2, Notch 3 and Notch 4 [1, 2]. The Notch receptor is a hetero-oligomer and a single-pass transmembrane receptor. The transmembrane monomer is bound through non-covalent interactions to a fully extracellular monomer. Notch is involved in cell proliferation, apoptosis, differentiation, survival and stabilization of arterial endothelial fate, angiogenesis and many other functions [3, 4]. Notch signaling is deregulated in many cancers including glioblastoma . The Notch receptor contains the extracellular peptide which contains EGF repeats that non-covalently associate with the transmembrane peptide and binds the Notch ligands (e.g. Delta and Jagged). Upon ligand binding, the Notch receptor is cleaved and sensitized by ADAM metalloproteases and gamma secretase. This leads to cleavage of NICD (Notch intracellular domain) to the nucleus, and the NICD forms a complex with CBF-1 and the transcriptional co-activator MAML for transcription of Notch genes . Previous studies have shown that inhibition of Notch signaling by pharmacological or genetic means leads to cell cycle arrest and suppression of cell growth [7–9].
We have shown that uPA and uPAR downregulation inhibits invasion in SNB19 glioma cells by decreasing phosphorylation of the Ras-activated FAK, p38MAPK, JNK and ERK1/2, as well as the MEK-activated phosphatidylinositol 3-kinase, AKT and mTOR pathway, indicative of a feedback signaling mechanism of the uPAR/uPA system . Moreover, studies have shown that Notch 1 signaling is known to cross talk with ERK, NF-κB and with the PI3-K/AKT/mTOR pathway . Notch has multiple roles in invasion and angiogenesis of many human cancers but the mechanisms are not understood [11, 12]. In this study, we have shown that down regulation of uPA and uPAR inhibits invasion of U251 MG cells and xenograft glioma cells by inhibition of Notch- related gene transcription, signaling mechanism and targeting Notch 1 to the lysosomal pathway. We have also shown that uPA/uPAR down regulation inhibits Notch 1 expression in pre-established tumors in nude mice. Overall, our results suggest that down regulation of uPA/uPAR, either singly or in combination, results in the inhibition of glioma cell invasion via inhibition of Notch 1 receptor cleavage, signaling and endosomal trafficking of the Notch 1 receptor.
Cells and Reagents
U251 MG cells were obtained from American Type Culture Collection, (Manassas, VA), and glioma xenograft cell lines (5310 & 4910) were kindly provided by Dr. David James (University of California, San Francisco, San Francisco, CA). All cell lines were cultured as described previously . Antibodies to Notch 1, 2, 3 and 4 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to cleaved Notch between Gly 1743 and Val 1744 were obtained from Cell Signaling (Beverly MA). Antibodies to extracellular domain of Notch were obtained from Abcam (Cambridge, UK). Antibodies to Delta and Jagged were obtained from Santa Cruz Biotechnology, (Santa Cruz, CA). Antibodies to RBPJκ, Lamin B, alpha tubulin, pAKT, NF-κB p65, MEK, pERK, pmTOR Ser 2448, were obtained from Cell Signaling (Beverly MA). Antibodies to uPA and uPAR were purchased from R&D Systems (Minneapolis, MN). Notch 1 siRNA and antibodies to GAPDH and LAMP-1 were purchased from SCBT (Santa Cruz, CA).
uPA and uPAR shRNA constructs
shRNA sequences targeting uPAR and uPA were constructed according to our previous publication .
Transfection with shRNA constructs
1.5 × 105 cells were plated in 100 mm petri dishes for each transfection experiment. The cells were transfected in serum-free L-15 media using 10 μg of Fugene reagent (Roche, USA) according to the manufacturer's instructions. The following constructs were used for transfection: puPA, puPAR, pU2 (both uPA and uPAR) and pSV (scrambled vector). No plasmid was introduced in the control plates. After 12 hrs of transfection, the serum-free media was replaced with serum-containing media and the cells were left in the incubator at 37°C for 48 hrs. The media was then replaced with serum-free media, and conditioned media was collected 12 hrs later. Cells were harvested for isolation of total RNA and/or total cell lysates. Conditioned media was used for fibrinogen plasminogen zymography.
Fibrinogen plasminogen zymography
We used fibrin zymography to determine the activity of the plasminogen activators as previously described . The samples were subjected to SDS-PAGE with 10% gels that contained fibrinogen and plasminogen. Following electrophoresis, the gels were washed twice with 2.5% (v/v) Triton X-100 for 30 min each time to remove SDS. Finally, the gels were incubated with 0.1 M glycine buffer (pH 7.5) at 37°C overnight, stained with amido black, and then destained. The final gel had a uniform background except in regions to which uPA had migrated and cleaved its substrate.
U251 MG, 5310 and 4910 cells were left untreated or transfected with puPA, puPAR or pU2. Cells were collected and whole cell lysates were prepared by lysing cells in RIPA lysis buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MO). Equal amounts of protein fractions, immunoprecipitates or lysates were resolved by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. Proteins were detected with appropriate primary antibodies followed by HRP-conjugated secondary antibodies. Comparable loading of proteins was verified by reprobing the blots with an antibody specific for the housekeeping gene product, GAPDH.
Reverse transcriptase polymerase chain reaction
Total RNA was isolated from U251MG, 4910 and 5310 cells using the TRIzol reagent as per the standard protocol. Total RNA was treated with DNAse I (Invitrogen, Carlsbad, CA) to remove contaminating genomic DNA. PCR analysis was done using the one-step reverse transcription-PCR kit (Invitrogen, Carlsbad, CA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. The following primers were used:
Notch 1 Forward 5'-CAGCTTGCACAACCAGACAGAC-3'
Notch 1 Reverse 5'-ACGGAGTACGGCCCATGTT-3'
Notch 2 Forward AACTGTCAGACCCTGGTGAAC
Notch 2 Reverse CGACAAGTGTAGCCTCCAATC
Notch 3 Forward TGACCGTACTGGCGAGACT
Notch 3 reverse CCGCTTGGCTGCATCAG
Notch 4 Forward AGTCCAGGCCTTGCCAGAACG
Notch 4 Reverse GTAGAAGGCATTGGCCAGAGAG
The PCR conditions were as follows: 95°C for 5 min., followed by 30 cycles of 95°C for 1 min., and annealing temperature set according to the AT and GC content of the primers.
NF-κB family transcription factor assay
Nuclear extracts from untreated U251 MG, 5310 and 4910 cells transfected with pSV, puPA, puPAR or pU2 were assayed for activation of NF-κB transcription factor by TransAM NF-κB family activation kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions.
U251 MG, 4910 and 5310 cells were either transfected with pSV, puPA, puPAR or pU2 or left untransfected. The cells were then fixed, permeabilized, stained with primary antibodies against Notch 1 and LAMP-1, washed, incubated with Alexa fluor tagged secondary antibodies, washed with PBS and mounted in an anti-fading reagent containing DAPI. The cells were then visualized using a confocal microscope using Olympus Fluoview software.
uPA/uPAR quantification by ELISA
Conditioned medium from mock and pSV, puPA, puPAR, or pU2-transfected U251 MG, 5310 and 4910 cells were subjected to ELISA for uPA and uPAR (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Soft colony agar assay
Anchorage independent growth was determined by assaying colony formation in soft agar . Briefly, U251 MG, 5310 and 4910 cells which were either untreated or transfected with pSV, puPA, puPAR or pU2 were suspended in DMEM or RPMI containing 10% FBS and 0.33% sea plaque low-melting temp agarose. 2 ml containing 2 × 104 cells were plated on a 35 mm dish over a 3 ml layer of solidified DMEM/RPMI 10% FBS and 0.6% agarose. The cells were fed by adding 200 μl of RPMI/10% FBS or with DMEM/10% FBS. The colonies were photographed at 10x and 20x magnification after 4 weeks.
Matrigel invasion assay
Invasion of U251MG and 4910 cells was determined by a Matrigel invasion assay as described previously . Briefly, U251MG, 4910 cells which were either left untreated, treated with DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester ( NICD inhibitor) for 1 h at 37°C or transfected with pSV, puPA, puPAR or pU2 were detached, washed twice in PBS, suspended in serum-free medium and seeded in the upper chamber of a Transwell insert (8-μm pores) coated with matrigel (1 mg ml-1) (Collaborative Research Inc., Boston, MA). The lower chamber was filled with 700 μl of complete medium. After 18 hrs of incubation period, the non-migrated cells in the upper chamber were gently scraped away, and invaded cells present on the lower surface of the insert were stained with Hema-3 (Fisher Diagnostics, Middletown, VA). Photographs of the invaded cells were taken with a light microscope (Olympus IX-71, Minneapolis, MN).
Co-localization of Notch 1 with LAMP-1
Semi-confluent U251 MG cells grown in 8-well chamber slides were left untreated or transfected with pSV,puPA, puPAR and pU2. After 48 hrs, the cells were washed, fixed with 2% paraformaldehyde, permeabilized in 0.5% Triton X-100, and stained with primary antibodies against Notch-1 and LAMP-1. The cells were then washed and further incubated with appropriate secondary Alexa fluor antibodies, and examined under an Olympus Fluoview microscope.
U251 MG cells (2 × 106) were injected into the brains of nude mice using a stereotactic frame. After 8-10 days the mice were treated with pSV, puPAR, puPA and pU2. The in vivo intracranial delivery of the vectors was performed using Alzet mini-osmotic pumps (Direct Corp, Cupertion, CA) at the rate of 0.25 μl/h [mock (PBS), 150 μg of Vector DNA, 150 μg of puPA, 150 μg of puPAR and 150 μg of pU2]. All experiments were performed in compliance with institutional guidelines established by the University Of Illinois College Of Medicine at Peoria. After five weeks or when the control mice started showing symptoms, mice were euthanized by cardiac perfusion with formaldehyde. The brains were then removed and paraffin embedded following standard protocols. Sections were prepared with H&E. In each case sections were blindly reviewed and scored semi-quantitatively for tumor size. Sections were observed and immunohistochemical analysis for Notch 1 was done on paraffin-embedded brain tumor sections of mice treated with pSV, puPA and pU2 with specific antibody for Notch 1.
Results and Discussion
Notch receptors are expressed in human glioblastoma tissue microarray and in glioblastoma cells and glioma xenograft cell lines
To determine if Notch is expressed in glioblastoma tissues and cells, we wanted to check for Notch receptor expression by GBM human tissue array, western blot and by RT-PCR in U251 MG, 4910 and 5310 cells. Consistent with previous reports, Notch 1, Notch 2, Notch 3 and Notch 4 expression by immunohistochemistry was observed in the GBM tissue array (Figure 1A, panels a, c, e, and g ). Notch receptors 1 to 4 were minimally expressed in normal brain tissue. (Figure 1A, panels b, d, f, h) Further confirmation of our GBM tissue array results was accomplished with immunofluorescent analysis (data not shown). Lysates from all the three cell lines showed expression of Notch 1, 2, 3, and 4 (Figure 1B) and results of mRNA analysis by RT-PCR also showed gene expression of all the four receptors (Figure 1C).
shRNA-mediated uPA/uPAR downregulation inhibits anchorage independent growth of U251 MG, 5310 and 4910 cells
U251 MG, 5310, 4910 cells were left untransfected or transfected with puPA, puPAR and pU2 were analyzed by a colony formation assay in soft agar (Figure 1D). puPA-, puPAR- and pU2-transfected U251 MG (Figure 1D, panel a to e), 5310 (Figure 1D, panel f to j) and 4910 (Figure 1D, panel k to o) cells showed significant decreases in colony number (**p < 0.0001). Quantitative analysis of the number of anchorage independent colonies in soft agar after shRNA transfection in U251 MG, 5310 and 4910 cells is shown in Figure 1E. The colony size was also decreased in the shRNA-transfected cells in comparison to the controls. A complete recovery in both colony number and size was obtained when exogenous uPA and ruPAR was added (data not shown) indicating a specific role for uPA and uPAR in anchorage-independent growth of U251, 5310 and 4910 cells. To further confirm our results, we performed a matrigel invasion assay in U251MG and 4910 cells left untransfected or transfected with SV, puPA, puPAR and pU2 and with DAPT (an NICD inhibitor). Results showed that invasion was inhibited in puPA, puPAR, pU2 and DAPT-treated conditions compared with controls, suggesting that inhibition of invasion by shRNA constructs against uPA, uPAR and U2 is mediated by Notch-1 receptor (Figure 1F).
puPA, puPAR and pU2 inhibit cleavage of Notch receptor in U251MG and xenograft cell lines
Notch receptor is cleaved by four enzymes and each cleaved product is significant to its function. However, cleavage of Notch 1 by gamma secretase is very critical for the function of the Notch receptor. Cleavage of Notch 1 by γ secreatase results in the release of NICD (Notch intracellular domain), and release of NICD to the nucleus is critical for Notch gene expression. In all of the three cell lines examined, we observed that puPA, puPAR and pU2 inhibited the cleavage of the Notch receptor as indicated by the absence of a cleaved band at 80 Kda compared with the controls (Figure 2A). Notch 1 is a transmembrane domain protein that is involved in the development and determination of cell fate . During maturation, the Notch molecule is cleaved by a furin-like convertase at its extracellular domain . Upon ligand binding, the carboxy terminal Notch 1 fragment is released and is further cleaved at Gly 1743 and Val 1744 [19, 20]. Endogenous levels of cytosolic domain are observed only upon cleavage between Gly 1743 and Val 1744. Results show cleavage of Notch at the Val 1744 position is inhibited in puPA- and pU2-transfected U251, 4910 and 5310 cells (Figure 2A). Quantitative representation of activated Notch 1 and cleaved Notch 1 levels is shown in Figure 2B and Figure 2C, respectively. To further confirm our western blotting results, we checked for the NICD domain in U251 MG cells by staining the cells with an antibody to NICD in untreated U251 MG cells and in U251 MG cells transfected with pSV, puPA, puPAR and pU2. As demonstrated by our western blot results, we observed increased expression of NICD in mock and pSV-treated cells (Figure 2D, panel a & b) while the cells treated with the three shRNA constructs showed very little staining (Figure 2D, panel c to e). NICD staining was seen as small green spots at the periphery and at the center of the cells.
puPA, puPAR and pU2 inhibits the gene expression of Notch 1 mRNA in all the three cell lines examined
To determine whether puPA, puPAR and pU2 inhibit Notch 1 mRNA, we subjected controls and shRNA-transfected U251 MG, 5310 and 4910 cells to RT PCR for Notch 1 gene expression. Results showed that simultaneous down regulation of uPA and uPAR by pU2 efficiently down regulated Notch 1 mRNA in all three cell lines compared with puPA and puPAR (Figure 2E). Quantitative analysis of the RT-PCR results is shown in Figure 2F. These results suggest that simultaneous down regulation of both uPA and uPAR with pU2 is a better approach to knockdown Notch 1 mRNA than using single shRNA constructs.
Notch inhibits uPA expression and activity in glioblastoma cells and xenografts
To ascertain whether Notch plays a role in regulating uPA activity and expression, we transfected U251 MG, 5310 and 4910 cells with scrambled vector siRNA and siRNA to Notch 1 and checked for uPA activity by fibrinogen zymography and uPA expression using western blotting. In all three cell lines tested, results showed that Notch siRNA downregulated uPA expression (Figure 3A) and uPA activity (Figure 3B). This probably suggests that Notch and uPA regulate each other through a positive feedback mechanism. Quantitative expression of relative uPA expression and relative uPA activity is shown in Figures 3C and Figure 3D, respectively.
Exogenous addition of uPA and uPAR activate Notch 1 in uPAR antisense and in U251 MG cells
Our previous results showed that shRNA against uPA and uPAR inhibits Notch expression and cleavage (Figure 2A). We wanted to check if addition of exogenous uPA and uPAR activates the Notch 1 receptor in uPAR antisense cells and in U251 MG cells. Our results indicate that upon exogenous addition of uPA and ruPAR, individually and in combination, Notch 1 expression was activated in uPAR antisense cells and in U251 MG cells (Figure 3E). This probably suggests that uPA independent of its role as a uPAR ligand can activate the Notch 1 receptor in glioblastoma cells.
uPA activates Notch 1 receptor independent of Notch ligands, Delta and Jagged
To further clarify the role of uPA as a ligand for Notch 1 in glioblastoma cells, we wanted to ascertain if uPA activates Notch 1 in uPAR antisense cells in both the presence and absence of Notch ligands, namely Delta and Jagged. For this purpose, we used siDelta and siJagged transfected uPAR antisense cells and stimulated these cells with uPA. Surprisingly, we found that in uPAR antisense cells, exogenous uPA activated Notch 1 and showed a further increase in fold activation in the presence of siDelta and Jagged siRNA (Figure 3F). These results suggest that Notch 1 can be activated by uPA by independent of uPAR and Notch ligands, Delta and Jagged. Quantitative expression of Notch 1 expression from Figure 3E & 3F is depicted in Figure 3G and Figure 3H, respectively. Overall, these results indicate that Notch 1 and uPA regulate each other in glioblastoma and GBM uPAR antisense cells.
puPA, puPAR and pU2 inhibits NICD and HES-induced AKT, NF-κB and ERK pathways in U251 MG and 4910 cells
Previously, we have shown that down regulation of uPA, uPAR and pU2 in SNB19 cells leads to decreased phosphorylation of AKT and mTOR at the Ser 2448 position, and ERK downstream of AKT. To further confirm these results in the cells lines used in this study, we checked for phosphorylation of AKT, ERK and mTOR after transfection with shRNA against uPA/uPAR, singly and in combination. As anticipated, we observed that transfection with puPA-, puPAR- and pU2-transfected cells significantly down regulated phosphorylation of AKT, mTOR and ERK pathways in the three cell lines used in this study. (Figure 4A-C). Previous studies have shown that NF-κB is a downstream target for ERK . To confirm whether uPA/uPAR downregulation inhibits NF-κB, which is downstream to ERK, we checked the nuclear activation of p50 (NF-κB1), p52 (NF-κB2) and p65 (Rel A). As expected, we observed significant reduction in the nuclear activation of p50, p52 and p65 in all three cell lines tested (Figure 4D-F). Overall, these results suggest that shRNA against uPA, uPAR and U2 inhibits AKT/mTOR, ERK and NF-κB pathways in glioblastoma cells and xenografts.
The cross talk between Notch signaling and AKT/mTOR pathways has been reported in the literature in many studies [22–24]. Previous reports in the literature [25, 26] have shown that there is a cross talk between Notch and NF-κB. To determine whether puPA down regulates Notch-induced AKT, NF-κB and ERK pathways, we overexpressed NICD and HES1 in U251 MG and 4910 cells. We also transfected these cells with puPA to check if puPA inhibits NICD and HES-induced phosphorylation of AKT, NF-κB and phosphorylation of ERK. Interestingly, we observed activation of AKT, ERK and NF-κB in pSV-transfected cells and in NICD and HES1-overexpressed cells (Figure 4G and 4H). AKT, ERK phosphorylation and NF-kB p65 levels were significantly down regulated upon transfection with puPA (Figure 4G and 4H). To confirm the cross talk of AKT/mTOR/NF- κB/ERK pathways with Notch-1, U251MG and 4910 cells were left untreated or treated with pSV and siNotch 1 and checked for the expression of pmTOR, pERK, pAKT and NF-kB p65. Results showed that siNotch 1 inhibited phosphorylation of AKT, ERK, mTOR and NF-kB levels compared with controls in both the cell lines tested (Figure 4I and Figure 4J). To further confirm if NICD/HES1-overexpressed Notch 1 is inhibited by puPA, puPAR and pU2 shRNA constructs, we checked for Notch 1 expression in U251MG and 4910 cells after transfection with shRNA constructs against uPA, uPAR and U2. Results showed that NICD/HES1 induced Notch1 expression levels were significantly reduced in uPA andU2 transfected cells and moderately in puPAR transfected cells (Figure 4K and Figure 4L). These results suggest that shRNA against uPA, uPAR and U2 inhibit AKT, ERK and NF- κB pathways. These results also show that shRNA against uPA down regulates NICD and HES-induced Notch1, AKT, NF-κB and ERK activation in glioblastoma cell lines.
Transcriptional inactivation of uPA/uPAR inhibits trafficking of Notch 1 receptor in the U251 MG cell line
The trafficking of Notch receptor is known to be mediated by endosomes. To determine if Notch 1 is targeted to lysosomes after transfection with shRNA against uPA, uPAR and U2 (bicistronic construct), we conducted immunofluorescent staining in U251 cells after transfection and checked for co-localization of NICD with LAMP-1 (a lysosomal marker). We did not observe co-localization of Notch 1 with LAMP-1 in mock and pSV-treated cells (Figure 5A, panel a to f) but there were few spots of co-localization in puPA- (Figure 5A, panel g to i) and puPAR- (Figure 5A, panel j to l) treated cells. In pU2-treated cells, we were able to observe a significant association of Notch 1 receptor with LAMP-1, as indicated by a significant number of yellow spots which is suggestive of co-localization (Figure 5A, panel m to o). The percent of cell count showing co-localization is depicted quantitatively in Figure 5B. This result suggests that Notch 1 receptor trafficking is significantly affected in puPA- puPAR- and pU2-transfected U251 MG cells.
puPA and pU2 affect growth and pre-established intracranial tumors in nude mice
To further confirm our in vitro results, we checked if shRNA against puPA and pU2 affected pre-established intracranial tumors in nude mice and also assessed Notch 1 expression. In U251 MG pre-established intracranial tumors, we observed expression of Notch 1 (Figure 6A, panel a to c), but in puPA-treated tumors, we observed a significant decrease in the tumor margin and infiltration, as well as in inhibition of Notch 1 expression (Figure 6A, panel d to f). In pU2-treated tumors, the tumor margin showed more inhibition than in puPA-treated tumors, and there was also significant inhibition of Notch 1 expression and more inhibition at the tumor margin than in puPA- treated tumors. (Figure 6A, panel g to i). Overall, these results show that uPA and uPAR down regulation in combination inhibits invasion in glioblastoma cells by down regulation of Notch 1 receptor activation and expression, as well as by blocking the trafficking of the Notch 1 receptor.
Expression of Notch 1 has been reported in various types of human cancers [27, 28]. Notch 1 has shown to be involved in several functions in cancer cells including proliferation, invasion and angiogenesis [21, 29, 30]. In this study, we report that Notch 1 is over expressed in glioblastoma cell line U251 MG and xenografts consistent with previous studies [11, 12, 31]. Studies by us and others have previously shown that simultaneous down regulation of uPA and uPAR in glioblastoma cells significantly down regulated invasion and angiogenesis by in vitro and in vivo [32, 33]. In this study, we found that Notch 1 is a direct target for puPA and by pU2. Studies by many groups [11, 34, 35] have shown that Notch 1 is target for many genes in glioblastoma, and siRNA against Notch 1 down regulates uPA and inhibits prostate cancer and pancreatic cancer cell invasion [27, 36]. Inspite of this current knowledge, the role of uPA and uPAR down regulation in glioma cell invasion remains poorly understood. In this study, we show that knockdown of uPA and uPAR in tandem inhibits cleavage of the Notch receptor, down regulates Notch 1 gene expression and Notch 1 signaling cross talk, and significantly blocks the trafficking of the Notch receptor in glioblastoma cells.
As previously shown in glioblastoma cell line SNB19, we observed that targeted down regulation of uPA and uPAR by single and bicistronic constructs inhibited invasion in U251 MG and in glioma xenografts 4910 and 5310 by Matrigel invasion assay (Figure 1F) and also anchorage independent growth by soft agar colony formation assay (Figure 1D). Increased expression of Notch 1 has been detected in brain tumors  and other cancers [38, 39]. The role of Notch 1 in different cancers is considerably varied . As previously reported , we observed increased expression of Notch 1 in glioma human tissue array, western blot and RT-PCR.
The down regulation of uPA and uPAR inhibited activated Notch 1 activity and cleavage of Notch 1 at the Val 1744 position which resulted in the inhibition of Notch gene transcription. Moreover, glioblastoma cells treated with siRNA against Notch showed decreased uPA expression as shown by western blotting and decreased uPA activity by fibrin zymography. Based on these observations, it is tempting to speculate that the uPA/uPAR system might play a direct role in Notch 1 signaling and that uPA alone could directly regulate Notch 1 in glioblastoma. Whether uPA/uPAR regulates Notch 1 promoter activity is to be studied in future. Our data corresponds to a previous study  which showed that Notch 1 knockdown regulates the expression of uPA and uPAR by a distinct gene expression mechanism in prostrate cancer cells. Bin Hafeez et al.  conclude their study by stating that in addition to MMP-9, uPA and uPAR might work synergistically to enhance tumor invasion and metastasis in prostrate cancer. As our results show that Notch 1 expression is severely altered with puPA, puPAR and pU2 treatments, we hypothesize that uPA/uPAR could be a target for intervention in glioma.
Previous studies have shown that Notch 1 regulates the PI3K/AKT/mTOR pathway in other cancers. Notch 1 has been reported to cross talk with the AKT pathway in human cancer cells [22–24, 42]. Studies by us have also shown that uPA and uPAR down regulation inhibits phosphorylation of Akt  in glioblastoma cells. Our results suggest that inhibition of AKT/mTOR signaling pathway via uPA/uPAR down regulation might be mediated by Notch 1 signaling in glioblastoma cells. Phosphorylation of AKT induced by NICD and HES 1 over expression was down regulated by shRNA against uPA in GBM cells. These results suggest the existence of a reciprocal regulation of Notch-1 and AKT pathway in uPA/uPAR down regulation in glioblastoma cells.
Notch is known to cross talk with NF-κB and ERK pathways which are downstream of AKT [27, 36]. Our studies have shown that uPA/uPAR down regulation inhibits nuclear activation of NF-κB  and phosphorylation of ERK . The present study has also shown that NF-κB and AKT induced by NICD and HES1 over expression in glioblastoma cell lines is inhibited by shRNA against uPA. Further in-depth mechanistic studies are required to understand the role of uPA in regulation of Notch 1-induced AKT, NF-κB and ERK pathways. Our results have comprehensively suggested that uPA/uPAR down regulation results in the inhibition of invasion of GBM cells by targeting the Notch 1 receptor signaling, cleavage, decreased Notch1 mRNA transcription and trafficking. Purow et al  have shown that Notch siRNA leads to increased cell death, decreased proliferation and inhibition of cell cycle in glioblastoma cells. Our results suggest that uPA/uPAR down regulation might regulate Notch 1-mediated events in glioblastoma. Interestingly, our results show that uPA/uPAR down regulation resulted in Delta and Jagged downregulation (data not shown). Studies by Purow et al  have also shown that Notch ligands could themselves have a potential for transformation and play important roles in gliomagenesis. How shRNA against uPA and uPAR regulates Delta and Jagged is under further investigation. Our results also show that in uPAR antisense cells and in U251 MG cells, uPA was able to activate Notch 1 in the absence of Delta and Jagged ligands. These results suggest that uPA by itself could mediate uPAR independent functions such as Notch 1 regulation in glioblastoma cell lines.
Our studies also indicate that uPA/uPAR down regulation also results in the lysosomal targeting of the Notch 1 receptor in U251 MG cells. The mechanistic details of lysosomal targeting are yet to be explored. Notch 1 expression was also inhibited in pupa- and pU2-treated pre-established intracranial tumors in nude mice. Involvement of uPA/uPAR in a plethora of cellular processes in glioma gives us the advantage of targeting this multifunctional system for therapeutic intervention in patients with high grade glioma.
In summary, we have presented experimental evidence that strongly suggests the role of Notch 1 in uPA/uPAR down regulation in glioblastoma. shRNA against uPA and uPAR inhibited Notch 1 cleavage, Notch gene transcription and Notch 1-mediated AKT/ERK phosphorylation and NF-κB subunits. From our results, we can conclude that down regulation of uPA/uPAR, singly and in tandem, could be an effective therapeutic approach for inactivation of Notch-1 cleavage, signaling and trafficking and to down regulate Notch-signaling-induced NF-κB, ERK and AKT pathways which are known to play roles in growth, migration, invasion and angiogenesis of glioblastoma. Based on our results, we provide a hypothetical pathway by which uPA/uPAR inhibits the Notch 1 pathway which may be partly mediated by AKT/NF-κB and ERK pathways. Overall, our results suggest that targeting uPA/uPAR may be advantageous for future treatment of gliomas.
This research was supported by a grant from National Institutes of Health, CA75557 (to J.S.R.). The contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
urokinase plasminogen activator
urokinase plasminogen activator receptor
RAC-alpha serine/threonine-protein kinase
phosphotidyl inositide 3 kinase
Extracellular regulated kinase
Notch intracellular domain: HES: Hairy enhancer of split
glyceraldehydephosphate 3 dehydrogenase
lysosome associated membrane protein 1.
Wang Z, Li Y, Banerjee S, Sarkar FH: Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008, 28: 3621-3630.
Leong KG, Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006, 107: 2223-2233. 10.1182/blood-2005-08-3329
Rehman AO, Wang CY: Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol. 2006, 16: 293-300. 10.1016/j.tcb.2006.04.003
Poellinger L, Lendahl U: Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr Opin Genet Dev. 2008, 18: 449-454. 10.1016/j.gde.2008.07.013
Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005, 15: 297-310.
Miele L: Notch signaling. Clin Cancer Res. 2006, 12: 1074-1079. 10.1158/1078-0432.CCR-05-2570
Xu P, Qiu M, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, Jiang H, Pu P: The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo. J Neurooncol. 2010, 97: 41-51. 10.1007/s11060-009-0007-1
Guo D, Ye J, Dai J, Li L, Chen F, Ma D, Ji C: Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk Res. 2009, 33: 678-685. 10.1016/j.leukres.2008.10.026
Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG: Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009, 69: 3060-3068.
Gondi CS, Kandhukuri N, Dinh DH, Gujrati M, Rao JS: Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol. 2007, 31: 19-27.
Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005, 65: 2353-2363. 10.1158/0008-5472.CAN-04-1890
Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, Pieper RO: Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007, 106: 417-427. 10.3171/jns.2007.106.3.417
Shaik S, Hirao H, Kumar D: Reactivity patterns of cytochrome P450 enzymes: multifunctionality of the active species, and the two states-two oxidants conundrum. Nat Prod Rep. 2007, 24: 533-552. 10.1039/b604192m
Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Kin Y, Fuller GN, Lakka SS, Kyritsis AP, Dinh DH, Olivero WC, Gujrati M, Yung WK, Rao JS: Stable transfection of urokinase-type plasminogen activator antisense construct modulates invasion of human glioblastoma cells. Clin Cancer Res. 2001, 7: 2519-2526.
Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA. 1995, 92: 1381-1385. 10.1073/pnas.92.5.1381
Nalla AK, Gorantla B, Gondi CS, Lakka SS, Rao JS: Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther. 2010, 17: 599-613. 10.1038/cgt.2010.16
Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science. 1999, 284: 770-776. 10.1126/science.284.5415.770
Chan YM, Jan YN: Roles for proteolysis and trafficking in notch maturation and signal transduction. Cell. 1998, 94: 423-426. 10.1016/S0092-8674(00)81583-4
Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998, 393: 382-386. 10.1038/30756
Rand MD, Grimm LM, rtavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, Aster JC: Calcium depletion dissociates and activates heterodimeric notch receptors. Mol Cell Biol. 2000, 20: 1825-1835. 10.1128/MCB.20.5.1825-1835.2000
Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, Wang CY: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005, 8: 13-23. 10.1016/j.ccr.2005.06.004
Gutierrez A, Look AT: NOTCH and PI3K-AKT pathways intertwined. Cancer Cell. 2007, 12: 411-413. 10.1016/j.ccr.2007.10.027
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, Cordon-Cardo C, Parsons R, Zuniga-Pflucker JC, Dominguez M, Ferrando AA: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007, 13: 1203-1210. 10.1038/nm1636
Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB: Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008, 118: 3660-3670. 10.1172/JCI36157
Osipo C, Golde TE, Osborne BA, Miele LA: Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest. 2008, 88: 11-17. 10.1038/labinvest.3700700
Song R, Kim YW, Koo BK, Jeong HW, Yoon MJ, Yoon KJ, Jun DJ, Im SK, Shin J, Kong MP, Kim KT, Yoon K, Kong YY: Mind bomb 1 in the lymphopoietic niches is essential for T and marginal zone B cell development. J Exp Med. 2008, 205: 2525-2536. 10.1084/jem.20081344
Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH: Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem. 2010, 109: 726-736.
Koch U, Radtke F: Notch and cancer: a double-edged sword. Cell Mol Life Sci. 2007, 64: 2746-2762. 10.1007/s00018-007-7164-1
Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalen M, Gerhardt H, Betsholtz C: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007, 445: 776-780. 10.1038/nature05571
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006, 444: 1032-1037. 10.1038/nature05355
Stockhausen MT, Kristoffersen K, Poulsen HS: The functional role of Notch signaling in human gliomas. Neuro Oncol. 2010, 12: 199-211.
Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS: Intraperitoneal injection of an hpRNA-expressing plasmid targeting uPAR and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res. 2007, 13: 4051-4060. 10.1158/1078-0432.CCR-06-3032
Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M, Rao JS: Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One. 2010, 5: e12458- 10.1371/journal.pone.0012458
Guessous F, Li Y, Abounader R: Signaling pathways in medulloblastoma. J Cell Physiol. 2008, 217: 577-583. 10.1002/jcp.21542
Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69: 7569-7576. 10.1158/0008-5472.CAN-09-0529
Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH: Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66: 2778-2784. 10.1158/0008-5472.CAN-05-4281
Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, Eberhart CG: Notch3 signaling initiates choroid plexus tumor formation. Oncogene. 2006, 25: 487-491.
Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991, 66: 649-661. 10.1016/0092-8674(91)90111-B
Stylianou S, Clarke RB, Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66: 1517-1525. 10.1158/0008-5472.CAN-05-3054
Liu J, Sato C, Cerletti M, Wagers A: Notch signaling in the regulation of stem cell self-renewal and differentiation. Curr Top Dev Biol. 2010, 92: 367-409.
Bin Hafeez B, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H: Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res. 2009, 15: 452-459. 10.1158/1078-0432.CCR-08-1631
Liu Y, Dehni G, Purcell KJ, Sokolow J, Carcangiu ML, rtavanis-Tsakonas S, Stifani S: Epithelial expression and chromosomal location of human TLE genes: implications for notch signaling and neoplasia. Genomics. 1996, 31: 58-64. 10.1006/geno.1996.0009
Wang Z, Kong D, Banerjee S, Li Y, Adsay NV, Abbruzzese J, Sarkar FH: Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67: 11377-11385. 10.1158/0008-5472.CAN-07-2803
The authors thank Shellee Abraham for manuscript preparation and Diana Meister and Sushma Jasti for manuscript review.
The authors declare there are no conflicts of interest regarding this manuscript.
HR conceived and carried out the experiments. HR wrote the manuscript. HR, CG and JSR reviewed and analyzed the data. JSR, MG and DD contributed reagents/materials/analysis tools. All members read and approved the final manuscript.